Page 80 - Mployee Wellness Programs News Today

A new PitchBook report listed several predictions for digital health companies in regards to weight loss drugs, including the potential for new weight loss startups and possible challenges for existing nutrition companies.

In a value-based partnership with ApolloMed, SCAN is launching a Provider Specific Plan called Compass. It is also announcing a Medicare Advantage plan designed for women called SCAN Inspired.

Avalyn Pharma aims to improve treatment of Idiopathic pulmonary fibrosis with inhalable versions of two older oral drugs and it’s now headed for mid-stage testing backed by a Series C financing. Other recent biotech industry financings raised money for research in cancer, immunology, and rare genetic diseases.

C-SNPs are Medicare Advantage plans formulated to meet the desired needs of people living with chronic diseases. These plans are different from traditional Medicare plans because they’re only available to people who fit the special needs category that the plan serves.

CEO of Alignment Health joins the Payer's Place and details how the growth of Medicare Advantage will only help patients in the future.

Right now, manufacturers are thriving. Hospitals are failing. And patients are suffering. We must stop this trend in its tracks by becoming better stewards of hospital resources and supply chains.

Midi Health's Series A funding round was led by Google Ventures. In total, Midi Health has raised $40 million, including from Felicis, Semper Virens, Icon, 25M and Operator Collective. The company offers virtual care for those going through perimenopause or menopause.

Preliminary weight loss and safety data for Structure Therapeutics’ drug candidate suggest it’s competitive with other oral GLP-1 targeting contenders from big pharma companies. The data are from a small study and a short time frame, but Structure was able to leverage the encouraging preliminary results into a private placement of securities.

It makes sense that when care navigation prioritizes the patient and better links them to care by reducing barriers and smoothing out the road to seeing a provider, the patient experiences better outcomes. Better outcomes also translates to fewer hospital readmissions, saving money for both patients and their employers.

Evvy's $14 million funding round was led by Left Lane Capital and included participation from General Catalyst, LabCorp Venture Fund, RH Capital, Ingeborg Investments, G9 Ventures, Virtue and Amboy Street Ventures. In total, Evvy has raised $19 million.